Navigation Links
ImpediMed and Metagenics Announce Agreement
Date:10/2/2008

BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. 2 /PRNewswire/ -- ImpediMed Ltd, a pioneer in the medical applications of bioimpedance technology and Metagenics, Inc., a global leader in science-based nutraceutical products, medical foods, and therapeutic lifestyle change programs, today announced an agreement to distribute ImpediMed technology in the United States and Canada. Metagenics' Australian affiliate, Health World, Ltd, has been a long-standing customer of the Brisbane-based medical device manufacturer.

"We've seen the synergies of combining ImpediMed's products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals," said Mike Katke, VP of Medical Marketing for San Clemente, California-based Metagenics. "Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision."

ImpediMed CEO Greg Brown said, "Metagenics has been an outstanding Australian partner using ImpediMed's body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles."

About Metagenics, Inc.

Metagenics, Inc. is a life sciences company and leading developer and manufacturer of science-based nutraceuticals medical foods, and therapeutic lifestyle change programs marketed to healthcare practitioners worldwide. It is headquartered in San Clemente, Calif. with manufacturing and multiple research facilities located in Gig Harbor, Wash., including its MetaProteomics(R) Nutrigenomics Research Center and its Functional Medicine Research Center(SM) for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NPA, NSF International, and TGA. For more information about Metagenics, please visit http://www.metagenics.com.

About ImpediMed Limited

ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of fluid status and body composition. ImpediMed's product range includes medical devices for body composition analysis and early detection and monitoring of secondary lymphedema in cancer survivors. ImpediMed's products are TGA and FDA cleared as well as CE marked for global distribution. For more information about ImpediMed, please visit http://www.impedimed.com

Contact:

Joseline Davison

Metagenics, Inc.

949-369-3406

josiedavison@metagenics.com

Jack Butler

ImpediMed

585-248-2554

jbutler@impedimed.com


'/>"/>
SOURCE ImpediMed Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
3. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
4. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
5. Synthetech Announces New Director of Manufacturing
6. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
7. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
8. Biotel Announces Record Revenues and Earnings for Fiscal 2008
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Helix BioPharma Announces $11.4 Million Private Placement
11. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):